Novartis (NVS)
(Delayed Data from NYSE)
$100.53 USD
-0.58 (-0.57%)
Updated May 24, 2024 04:00 PM ET
After-Market: $100.52 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Price, Consensus and EPS Surprise
NVS 100.53 -0.58(-0.57%)
Will NVS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for NVS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVS
Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
NVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roche (RHHBY) Cancer Drug Gets Breakthrough Therapy Designation
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Other News for NVS
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
Jefferies healthcare analyst holds an analyst/industry conference call
Dodge & Cox International Stock Fund Q1 2024 Shareholder Letter